<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37189823</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>18</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1206</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines11041206</ELocationID><Abstract><AbstractText>Atherosclerosis is a chronic inflammatory and degenerative process that mainly occurs in large- and medium-sized arteries and is morphologically characterized by asymmetric focal thickenings of the innermost layer of the artery, the intima. This process is the basis of cardiovascular diseases (CVDs), the most common cause of death worldwide. Some studies suggest a bidirectional link between atherosclerosis and the consequent CVD with COVID-19. The aims of this narrative review are (1) to provide an overview of the most recent studies that point out a bidirectional relation between COVID-19 and atherosclerosis and (2) to summarize the impact of cardiovascular drugs on COVID-19 outcomes. A growing body of evidence shows that COVID-19 prognosis in individuals with CVD is worse compared with those without. Moreover, various studies have reported the emergence of newly diagnosed patients with CVD after COVID-19. The most common treatments for CVD may influence COVID-19 outcomes. Thus, their implication in the infection process is briefly discussed in this review. A better understanding of the link among atherosclerosis, CVD, and COVID-19 could proactively identify risk factors and, as a result, develop strategies to improve the prognosis for these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vilaplana-Carnerero</LastName><ForeName>Carles</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3780-4996</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), 08007 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Universitat Aut&#xf2;noma de Barcelona, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giner-Soriano</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3750-9233</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), 08007 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Universitat Aut&#xf2;noma de Barcelona, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dominguez</LastName><ForeName>&#xc0;ngela</ForeName><Initials>&#xc0;</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Consortium in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morros</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), 08007 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Consortium in Infectious Diseases (CIBERINFEC), 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Therapeutics and Toxicology, School of Medicine, Universitat Aut&#xf2;noma de Barcelona, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericas</LastName><ForeName>Carles</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6481-452X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology Service, Public Health Agency of Barcelona (ASPB), 08023 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lamo-Junquera</LastName><ForeName>Dolores</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Quality, Process and Innovation Direction, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Services Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toledo</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0794-9238</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Consortium in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallego</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Methodology, Quality and Medical Care Assessment Department, Direcci&#xf3; d'Atenci&#xf3; Prim&#xe0;ria Metropolitana Sud, Catalan Institute of Health (ICS), 08908 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redondo</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital Universitario Bellvitge, Catalan Institute of Health (ICS), 08907 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grau</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2807-8136</Identifier><AffiliationInfo><Affiliation>Biomedical Research Consortium in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Serra H&#xfa;nter Fellow, Department of Medicine, School of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">atherosclerosis</Keyword><Keyword MajorTopicYN="N">bidirectional link</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">cardiovascular disease treatments</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37189823</ArticleId><ArticleId IdType="pmc">PMC10136342</ArticleId><ArticleId IdType="doi">10.3390/biomedicines11041206</ArticleId><ArticleId IdType="pii">biomedicines11041206</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard. World Health Organization; Geneva, Switzerland: 2023.  [(accessed on 14 March 2023)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Ma Y., Deng J., Liu Q., Du M., Liu M., Liu J. Long-term consequences of COVID-19 at 6 months and above: A systematic review and meta-analysis. Int. J. Environ. Res. Public Health. 2022;19:6865. doi: 10.3390/ijerph19116865.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19116865</ArticleId><ArticleId IdType="pmc">PMC9180091</ArticleId><ArticleId IdType="pubmed">35682448</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey-Re&#xf1;ones C., Martinez-Torres S., Mart&#xed;n-Luj&#xe1;n F.M., Pericas C., Redondo A., Vilaplana-Carnerero C., Dominguez A., Grau M. Type 2 diabetes mellitus and COVID-19: A narrative review. Biomedicines. 2022;10:2089. doi: 10.3390/biomedicines10092089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10092089</ArticleId><ArticleId IdType="pmc">PMC9495673</ArticleId><ArticleId IdType="pubmed">36140191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.C.E., Ali K., Connell D., Mordi I.R., George J., Lang E.M., Lang C.C. COVID-19-associated cardiovascular complications. Diseases. 2021;9:47. doi: 10.3390/diseases9030047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases9030047</ArticleId><ArticleId IdType="pmc">PMC8293160</ArticleId><ArticleId IdType="pubmed">34209705</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg M., Maralakunte M., Garg S., Dhooria S., Sehgal I., Bhalla A.S., Vijayvergiya R., Grover S., Bhatia V., Jagia P., et al. The conundrum of &#x2018;Long-COVID-19&#x2019;: A narrative review. Int. J. Gen. Med. 2021;14:2491&#x2013;2506. doi: 10.2147/IJGM.S316708.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S316708</ArticleId><ArticleId IdType="pmc">PMC8214209</ArticleId><ArticleId IdType="pubmed">34163217</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeherman S., Suzuki Y.J. Viral infection and cardiovascular disease: Implications for the molecular basis of COVID-19 pathogenesis. Int. J. Mol. Sci. 2021;22:1659. doi: 10.3390/ijms22041659.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22041659</ArticleId><ArticleId IdType="pmc">PMC7914972</ArticleId><ArticleId IdType="pubmed">33562193</ArticleId></ArticleIdList></Reference><Reference><Citation>Streblow D.N., Orloff S.L., Nelson J.A. Do pathogens accelerate atherosclerosis? J. Nutr. 2001;131:2798S&#x2013;2804S. doi: 10.1093/jn/131.10.2798S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/131.10.2798S</ArticleId><ArticleId IdType="pubmed">11584110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunutsor S.K., Laukkanen J.A. Cardiovascular complications in COVID-19: A systematic review and meta-analysis. J. Infect. 2020;81:e139&#x2013;e141. doi: 10.1016/j.jinf.2020.05.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.05.068</ArticleId><ArticleId IdType="pmc">PMC7832225</ArticleId><ArticleId IdType="pubmed">32504747</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal G., Cheruiyot I., Aggarwal S., Wong J., Lippi G., Lavie C.J., Henry B.M., Sanchis-Gomar F. Association of cardiovascular disease with coronavirus disease 2019 (COVID-19) severity: A meta-analysis. Curr. Probl. Cardiol. 2020;45:100617. doi: 10.1016/j.cpcardiol.2020.100617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2020.100617</ArticleId><ArticleId IdType="pmc">PMC7187816</ArticleId><ArticleId IdType="pubmed">32402515</ArticleId></ArticleIdList></Reference><Reference><Citation>Madjid M., Aboshady I., Awan I., Litovsky S., Casscells S.W. Influenza and cardiovascular disease: Is there a causal relationship? Tex. Heart Inst. J. 2004;31:4&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387426</ArticleId><ArticleId IdType="pubmed">15061620</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalili M., Sayehmiri K., Ansari N., Pourhossein B., Fazeli M., Azizi Jalilian F. Association between influenza and COVID-19 viruses and the risk of atherosclerosis: Meta-analysis study and systematic review. Adv. Respir. Med. 2022;90:338&#x2013;348. doi: 10.3390/arm90040043.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/arm90040043</ArticleId><ArticleId IdType="pmc">PMC9717337</ArticleId><ArticleId IdType="pubmed">36004963</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005;352:1685&#x2013;1695. doi: 10.1056/NEJMra043430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra043430</ArticleId><ArticleId IdType="pubmed">15843671</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P., Buring J.E., Badimon L., Hansson G.K., Deanfield J., Bittencourt M.S., Tokg&#xf6;zo&#x11f;lu L., Lewis E.F. Atherosclerosis. Nat. Rev. Dis. Prim. 2019;5:56. doi: 10.1038/s41572-019-0106-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0106-z</ArticleId><ArticleId IdType="pubmed">31420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Makarova Y.A., Ryabkova V.A., Salukhov V.V., Sagun B.V., Korovin A.E., Churilov L.P. Atherosclerosis, cardiovascular disorders and COVID-19: Comorbid pathogenesis. Diagnostics. 2023;13:478. doi: 10.3390/diagnostics13030478.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics13030478</ArticleId><ArticleId IdType="pmc">PMC9914751</ArticleId><ArticleId IdType="pubmed">36766583</ArticleId></ArticleIdList></Reference><Reference><Citation>Frosteg&#xe5;rd J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117. doi: 10.1186/1741-7015-11-117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-117</ArticleId><ArticleId IdType="pmc">PMC3658954</ArticleId><ArticleId IdType="pubmed">23635324</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves S.S., Nealon J., Burkart K.G., Modin D., Biering-S&#xf8;rensen T., Ortiz J.R., Vilchis-Tella V.M., Wallace L.E., Roth G., Mahe C., et al. Global, regional and national estimates of influenza-attributable ischemic heart disease mortality. EClinicalMedicine. 2022;55:101740. doi: 10.1016/j.eclinm.2022.101740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101740</ArticleId><ArticleId IdType="pmc">PMC9678904</ArticleId><ArticleId IdType="pubmed">36425868</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed S., Tadic M., Larsen T.H., Grassi G., Mancia G. Coronavirus disease 2019 and cardiovascular complications: Focused clinical review. J. Hypertens. 2021;39:1282&#x2013;1292. doi: 10.1097/HJH.0000000000002819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000002819</ArticleId><ArticleId IdType="pmc">PMC9904438</ArticleId><ArticleId IdType="pubmed">33687179</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T., Luo S., Libby P., Shi G.P. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. Pharmacol. Ther. 2020;213:107587. doi: 10.1016/j.pharmthera.2020.107587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2020.107587</ArticleId><ArticleId IdType="pmc">PMC7255230</ArticleId><ArticleId IdType="pubmed">32470470</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi H.K., Libby P., Ridker P.M. COVID-19&#x2014;A vascular disease. Trends Cardiovasc. Med. 2021;31:1&#x2013;5. doi: 10.1016/j.tcm.2020.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2020.10.005</ArticleId><ArticleId IdType="pmc">PMC7556303</ArticleId><ArticleId IdType="pubmed">33068723</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiga M., Wang D.W., Han Y., Lewis D.B., Wu J.C. COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives. Nat. Rev. Cardiol. 2020;17:543&#x2013;558. doi: 10.1038/s41569-020-0413-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0413-9</ArticleId><ArticleId IdType="pmc">PMC7370876</ArticleId><ArticleId IdType="pubmed">32690910</ArticleId></ArticleIdList></Reference><Reference><Citation>Grzegorowska O., Lorkowski J. Possible correlations between atherosclerosis, acute coronary syndromes and COVID-19. J. Clin. Med. 2020;9:3746. doi: 10.3390/jcm9113746.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9113746</ArticleId><ArticleId IdType="pmc">PMC7700642</ArticleId><ArticleId IdType="pubmed">33233333</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagris M., Theofilis P., Antonopoulos A.S., Tsioufis C., Oikonomou E., Antoniades C., Crea F., Kaski J.C., Tousoulis D. Inflammatory mechanisms in COVID-19 and atherosclerosis: Current pharmaceutical perspectives. Int. J. Mol. Sci. 2021;22:6607. doi: 10.3390/ijms22126607.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22126607</ArticleId><ArticleId IdType="pmc">PMC8234423</ArticleId><ArticleId IdType="pubmed">34205487</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Dong Y., Wang H., Guo W., Zhou H., Zhang Z., Tian C., Du K., Zhu R., Wang L., et al. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. Nutr. Metab. Cardiovasc. Dis. 2020;30:1061&#x2013;1067. doi: 10.1016/j.numecd.2020.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2020.04.013</ArticleId><ArticleId IdType="pmc">PMC7165120</ArticleId><ArticleId IdType="pubmed">32456948</ArticleId></ArticleIdList></Reference><Reference><Citation>Raisi-Estabragh Z., Cooper J., Salih A., Raman B., Lee A.M., Neubauer S., Harvey N.C., Petersen S.E. Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank. Heart. 2022;109:119&#x2013;126. doi: 10.1136/heartjnl-2022-321492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2022-321492</ArticleId><ArticleId IdType="pmc">PMC9811071</ArticleId><ArticleId IdType="pubmed">36280346</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y., Ling Y., Bai T., Xie Y., Huang J., Li J., Xiong W., Yang D., Chen R., Lu F., et al. COVID-19 with different severities: A multicenter study of clinical features. Am. J. Respir. Crit. Care Med. 2020;201:1380&#x2013;1388. doi: 10.1164/rccm.202002-0445OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202002-0445OC</ArticleId><ArticleId IdType="pmc">PMC7258639</ArticleId><ArticleId IdType="pubmed">32275452</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinciguerra M., Romiti S., Fattouch K., De Bellis A., Greco E. Atherosclerosis as Pathogenetic Substrate for SARS-CoV2 Cytokine Storm. J. Clin. Med. 2020;9:2095. doi: 10.3390/jcm9072095.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9072095</ArticleId><ArticleId IdType="pmc">PMC7408959</ArticleId><ArticleId IdType="pubmed">32635302</ArticleId></ArticleIdList></Reference><Reference><Citation>Clerkin K.J., Fried J.A., Raikhelkar J., Sayer G., Griffin J.M., Masoumi A., Jain S.S., Burkhoff D., Kumaraiah D., Rabbani L., et al. COVID-19 and cardiovascular disease. Circulation. 2020;141:1648&#x2013;1655. doi: 10.1161/CIRCULATIONAHA.120.046941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.046941</ArticleId><ArticleId IdType="pubmed">32200663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazcano U., Cuadrado-Godia E., Grau M., Subirana I., Mart&#xed;nez-Carbonell E., Boher-Massaguer M., Rodr&#xed;guez-Campello A., Giralt-Steinhauer E., Fern&#xe1;ndez-P&#xe9;rez I., Jim&#xe9;nez-Conde J., et al. Increased COVID-19 mortality in people with previous cerebrovascular disease: A population-based cohort study. Stroke. 2022;53:276&#x2013;1284. doi: 10.1161/STROKEAHA.121.036257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.121.036257</ArticleId><ArticleId IdType="pubmed">34781706</ArticleId></ArticleIdList></Reference><Reference><Citation>Naeini M.B., Sahebi M., Nikbakht F., Jamshidi Z., Ahmadimanesh M., Hashemi M., Ramezani J., Miri H.H., Yazdian-Robati R. A meta-meta-analysis: Evaluation of meta-analyses published in the effectiveness of cardiovascular comorbidities on the severity of COVID-19. Obes. Med. 2021;22:100323. doi: 10.1016/j.obmed.2021.100323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.obmed.2021.100323</ArticleId><ArticleId IdType="pmc">PMC7826091</ArticleId><ArticleId IdType="pubmed">33521379</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellicori P., Doolub G., Wong C.M., Lee K.S., Mangion K., Ahmad M., Berry C., Squire I., Lambiase P.D., Lyon A., et al. COVID-19 and its cardiovascular effects: A systematic review of prevalence studies. Cochrane Database Syst. Rev. 2021;3:CD013879. doi: 10.1002/14651858.CD013879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013879</ArticleId><ArticleId IdType="pmc">PMC8078349</ArticleId><ArticleId IdType="pubmed">33704775</ArticleId></ArticleIdList></Reference><Reference><Citation>Khawaja S.A., Mohan P., Jabbour. R., Bampouri. T., Bowsher G., Hassan A.M.M., Huq F., Baghdasaryan L., Wang B., Sethi A., et al. COVID-19 and its impact on the cardiovascular system. Open Heart. 2021;8:e001472. doi: 10.1136/openhrt-2020-001472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2020-001472</ArticleId><ArticleId IdType="pmc">PMC7969760</ArticleId><ArticleId IdType="pubmed">33723014</ArticleId></ArticleIdList></Reference><Reference><Citation>Hessami A., Shamshirian A., Heydari K., Pourali F., Alizadeh-Navaei R., Moosazadeh M., Abrotan S., Shojaie L., Sedighi S., Shamshirian D., et al. Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. Am. J. Emerg. Med. 2021;46:382&#x2013;391. doi: 10.1016/j.ajem.2020.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.10.022</ArticleId><ArticleId IdType="pmc">PMC7561581</ArticleId><ArticleId IdType="pubmed">33268238</ArticleId></ArticleIdList></Reference><Reference><Citation>Buja L.M., Wolf D.A., Zhao B., Akkanti B., McDonald M., Lelenwa L., Reilly N., Ottaviani G., Elghetany M.T., Trujillo D.O., et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc. Pathol. 2020;48:107233. doi: 10.1016/j.carpath.2020.107233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carpath.2020.107233</ArticleId><ArticleId IdType="pmc">PMC7204762</ArticleId><ArticleId IdType="pubmed">32434133</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Xiao W., Liang X., Shi L., Zhang P., Wang Y., Wang Y., Yang H. A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity. BMC Public Health. 2021;21:1533. doi: 10.1186/s12889-021-11051-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-11051-w</ArticleId><ArticleId IdType="pmc">PMC8355578</ArticleId><ArticleId IdType="pubmed">34380456</ArticleId></ArticleIdList></Reference><Reference><Citation>Collard D., Nurmohamed N.S., Kaiser Y., Reeskamp L.F., Dormans T., Moeniralam H., Simsek S., Douma R., Eerens A., Reidinga A.C., et al. Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: A prospective cohort study. BMJ Open. 2021;11:e045482. doi: 10.1136/bmjopen-2020-045482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-045482</ArticleId><ArticleId IdType="pmc">PMC7902321</ArticleId><ArticleId IdType="pubmed">33619201</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostaza J.M., Salinero-Fort M.A., Cardenas-Valladolid J., Rodriguez-Artalejo F., D&#xed;az-Almiron M., Vich-P&#xe9;rez P., San Andres-Rebollo F.J., Vicente I., Lahoz C. Pre-infection HDL-cholesterol levels and mortality among elderly patients infected with SARS-CoV-2. Atherosclerosis. 2022;341:13&#x2013;19. doi: 10.1016/j.atherosclerosis.2021.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2021.12.009</ArticleId><ArticleId IdType="pmc">PMC8692242</ArticleId><ArticleId IdType="pubmed">34959204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathi M., Vakili K., Sayehmiri F., Mohamadkhani A., Hajiesmaeili M., Rezaei-Tavirani M., Eilami O. The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. PLoS ONE. 2021;16:e0246190. doi: 10.1371/journal.pone.0246190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246190</ArticleId><ArticleId IdType="pmc">PMC7886178</ArticleId><ArticleId IdType="pubmed">33592019</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang C., Zhang W., Li S., Qin G. Coronary heart disease and COVID-19: A meta-analysis. Med. Clin. 2021;156:547&#x2013;554. doi: 10.1016/j.medcli.2020.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medcli.2020.12.017</ArticleId><ArticleId IdType="pmc">PMC7843088</ArticleId><ArticleId IdType="pubmed">33632508</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Guimaraes M., Moj&#xf3;n D., Calvo A., Izquierdo A., Belarte-Tornero L., Salvatella N., Llagostera M., Negrete A., Mas-Stachurska A., Ruiz S., et al. Influence of cardiovascular disease and cardiovascular risk factors in COVID-19 patients. Data from a large prospective Spanish cohort. REC CardioClin. 2021;56:108&#x2013;117.</Citation></Reference><Reference><Citation>Sheppard J.P., Nicholson B.D., Lee J., McGagh D., Sherlock J., Koshiaris C., Oke J., Jones N.R., Hinton W., Armitage L., et al. Association between blood pressure control and coronavirus disease 2019 outcomes in 45&#x2009;418 symptomatic patients with hypertension: An observational cohort study. Hypertension. 2021;77:846&#x2013;855. doi: 10.1161/HYPERTENSIONAHA.120.16472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.16472</ArticleId><ArticleId IdType="pmc">PMC7884248</ArticleId><ArticleId IdType="pubmed">33325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahat R.K., Rathore V., Singh N., Singh N., Singh S.-K., Shah R.K., Garg C. Lipid profile as an indicator of COVID-19 severity: A systematic review and meta-analysis. Clin. Nutr. ESPEN. 2021;45:91&#x2013;101. doi: 10.1016/j.clnesp.2021.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnesp.2021.07.023</ArticleId><ArticleId IdType="pmc">PMC8325550</ArticleId><ArticleId IdType="pubmed">34620375</ArticleId></ArticleIdList></Reference><Reference><Citation>Arif Y.A., Stefanko A.M., Garcia N., Beshai D.A., Fan W., Wong N.D. Estimated atherosclerotic cardiovascular disease risk: Disparities and severe COVID-19 outcomes (from the National COVID Cohort Collaborative) Am. J. Cardiol. 2022;183:16&#x2013;23. doi: 10.1016/j.amjcard.2022.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2022.08.011</ArticleId><ArticleId IdType="pmc">PMC9513339</ArticleId><ArticleId IdType="pubmed">36175254</ArticleId></ArticleIdList></Reference><Reference><Citation>Budoff M.J., Mayrhofer T., Ferencik M., Bittner D., Lee K.L., Lu M.T., Coles A., Jang J., Krishnam M., Douglas P.S., et al. PROMISE Investigators. Prognostic value of coronary artery calcium in the PROMISE Study (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) Circulation. 2017;136:1993&#x2013;2005. doi: 10.1161/CIRCULATIONAHA.117.030578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.030578</ArticleId><ArticleId IdType="pmc">PMC5698136</ArticleId><ArticleId IdType="pubmed">28847895</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotlo S., Thorgerson A., Kulinski J. Coronary artery calcification as a predictor of adverse outcomes in patients hospitalized with COVID-19. Am. Heart J. Plus. 2023;28:100288. doi: 10.1016/j.ahjo.2023.100288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahjo.2023.100288</ArticleId><ArticleId IdType="pmc">PMC9993728</ArticleId><ArticleId IdType="pubmed">36925617</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.K., Rahimi O., Lee C.K., Shafi A., Hawwass D. A Meta-analysis: Coronary artery calcium score and COVID-19 prognosis. Med. Sci. 2022;10:5. doi: 10.3390/medsci10010005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medsci10010005</ArticleId><ArticleId IdType="pmc">PMC8883990</ArticleId><ArticleId IdType="pubmed">35225939</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., Ji R., Wang H., Wang Y., Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int. J. Infect. Dis. 2020;94:91&#x2013;95. doi: 10.1016/j.ijid.2020.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.03.017</ArticleId><ArticleId IdType="pmc">PMC7194638</ArticleId><ArticleId IdType="pubmed">32173574</ArticleId></ArticleIdList></Reference><Reference><Citation>Emami A., Javanmardi F., Pirbonyeh N., Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: A systematic review and meta-analysis. Arch. Acad. Emerg. Med. 2020;8:e35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096724</ArticleId><ArticleId IdType="pubmed">32232218</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillarisetti J., Cheema M.S., Haloot J., Panday M., Badin A., Mehta A., Anderson A.S., Prasad A. Cardiac complications of COVID-19: Incidence and outcomes. Indian Heart J. 2022;74:170&#x2013;177. doi: 10.1016/j.ihj.2022.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ihj.2022.04.008</ArticleId><ArticleId IdType="pmc">PMC9050189</ArticleId><ArticleId IdType="pubmed">35490848</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.C., Hsu C.K., Yen M.Y., Lee P.I., Ko W.C., Hsueh P.R. Long COVID: An inevitable sequela of SARS-CoV-2 infection. J. Microbiol. Immunol. Infect. 2023;56:1&#x2013;9. doi: 10.1016/j.jmii.2022.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2022.10.003</ArticleId><ArticleId IdType="pmc">PMC9576029</ArticleId><ArticleId IdType="pubmed">36283919</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobler D.L., Pruzansky A.J., Naderi S., Ambrosy A.P., Slade J.J. Long-term cardiovascular effects of COVID-19: Emerging data relevant to the cardiovascular clinician. Curr. Atheroscler. Rep. 2022;24:563&#x2013;570. doi: 10.1007/s11883-022-01032-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11883-022-01032-8</ArticleId><ArticleId IdType="pmc">PMC9065238</ArticleId><ArticleId IdType="pubmed">35507278</ArticleId></ArticleIdList></Reference><Reference><Citation>Maestre-Mu&#xf1;iz M.M., Arias &#xc1;., Mata-V&#xe1;zquez E., Mart&#xed;n-Toledano M., L&#xf3;pez-Larramona G., Ruiz-Chicote A.M., Nieto-Sandoval B., Lucendo A.J. Long-term outcomes of patients with coronavirus disease 2019 at one year after hospital discharge. J. Clin. Med. 2021;10:2945. doi: 10.3390/jcm10132945.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10132945</ArticleId><ArticleId IdType="pmc">PMC8269002</ArticleId><ArticleId IdType="pubmed">34209085</ArticleId></ArticleIdList></Reference><Reference><Citation>Negreira-Caama&#xf1;o M., Mart&#xed;nez-Del R&#xed;o J., &#xc1;guila-Gordo D., Mateo-G&#xf3;mez C., Soto-P&#xe9;rez M., Piqueras-Flores J. Cardiovascular events after COVID-19 hospitalization: Long-term follow-up. Rev. Esp. Cardiol. (Engl. Ed.) 2022;75:100&#x2013;102. doi: 10.1016/j.rec.2021.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rec.2021.09.001</ArticleId><ArticleId IdType="pmc">PMC8426288</ArticleId><ArticleId IdType="pubmed">34583913</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Wang C.Y., Wang S.I., Wei J.C. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619. doi: 10.1016/j.eclinm.2022.101619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101619</ArticleId><ArticleId IdType="pmc">PMC9366236</ArticleId><ArticleId IdType="pubmed">35971425</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight R., Walker V., Ip S., Cooper J.A., Bolton T., Keene S., Denholm R., Akbari A., Abbasizanjani H., Torabi F., et al. CVD-COVID-UK/COVID-IMPACT Consortium and the Longitudinal Health and Wellbeing COVID-19 National Core Study. Association of COVID-19 with major arterial and venous thrombotic diseases: A population-wide cohort study of 48 million adults in England and Wales. Circulation. 2022;146:892&#x2013;906. doi: 10.1161/CIRCULATIONAHA.122.060785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.060785</ArticleId><ArticleId IdType="pmc">PMC9484653</ArticleId><ArticleId IdType="pubmed">36121907</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezel-Potts E., Douiri A., Sun X., Chowienczyk P.J., Shah A.M., Gulliford M.C. Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK. PLoS Med. 2022;19:e1004052. doi: 10.1371/journal.pmed.1004052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004052</ArticleId><ArticleId IdType="pmc">PMC9295991</ArticleId><ArticleId IdType="pubmed">35853019</ArticleId></ArticleIdList></Reference><Reference><Citation>Task Force for the management of COVID-19 of the European Society of Cardiology European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 1-epidemiology, pathophysiology, and diagnosis. Eur. Heart J. 2022;43:1033&#x2013;1058. doi: 10.1093/eurheartj/ehab696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab696</ArticleId><ArticleId IdType="pmc">PMC8690026</ArticleId><ArticleId IdType="pubmed">34791157</ArticleId></ArticleIdList></Reference><Reference><Citation>Task Force for the management of COVID-19 of the European Society of Cardiology ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 2-care pathways, treatment, and follow-up. Cardiovasc. Res. 2022;118:1618&#x2013;1666. doi: 10.1093/cvr/cvab343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvab343</ArticleId><ArticleId IdType="pmc">PMC8690236</ArticleId><ArticleId IdType="pubmed">34864876</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ani F., Chehade S., Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb. Res. 2020;192:152&#x2013;160. doi: 10.1016/j.thromres.2020.05.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.05.039</ArticleId><ArticleId IdType="pmc">PMC7255332</ArticleId><ArticleId IdType="pubmed">32485418</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham S., Nohria A., Neilan T.G., Asnani A., Saji A.M., Shah J., Lech T., Grossman J., Abraham G.M., McQuillen D.P., et al. Cardiovascular drug interactions with nirmatrelvir/ritonavir in patients with COVID-19: JACC review topic of the week. J. Am. Coll. Cardiol. 2022;80:1912&#x2013;1924. doi: 10.1016/j.jacc.2022.08.800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.08.800</ArticleId><ArticleId IdType="pmc">PMC9580069</ArticleId><ArticleId IdType="pubmed">36243540</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med. 2020;8:e21. doi: 10.1016/S2213-2600(20)30116-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30116-8</ArticleId><ArticleId IdType="pmc">PMC7118626</ArticleId><ArticleId IdType="pubmed">32171062</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu L., Liu X., Su Y., Ma J., Hong K. Prevalence and impact of cardiac injury on COVID-19: A systematic review and meta-analysis. Clin. Cardiol. 2021;44:276&#x2013;283. doi: 10.1002/clc.23540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.23540</ArticleId><ArticleId IdType="pmc">PMC7852167</ArticleId><ArticleId IdType="pubmed">33382482</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Fu W., Zhu C.J., Ding Z.H., Dong B.B., Sun B.Q., Chen R.C. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: A systematic review, meta-analysis, and meta-regression analysis. BMC Infect. Dis. 2023;23:53. doi: 10.1186/s12879-023-07994-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-07994-7</ArticleId><ArticleId IdType="pmc">PMC9872739</ArticleId><ArticleId IdType="pubmed">36694122</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Wang X., Chen J., Zhang H., Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;5:825&#x2013;830. doi: 10.1001/jamacardio.2020.1624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1624</ArticleId><ArticleId IdType="pmc">PMC7180726</ArticleId><ArticleId IdType="pubmed">32324209</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancia G., Rea F., Ludergnani M., Apolone G., Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N. Engl. J. Med. 2020;382:2431&#x2013;2440. doi: 10.1056/NEJMoa2006923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2006923</ArticleId><ArticleId IdType="pmc">PMC7206933</ArticleId><ArticleId IdType="pubmed">32356627</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroon S., Subramanian A., Cooper J., Anand A., Gokhale K., Byne N., Dhalla S., Acosta-Mena D., Taverner T., Okoth K., et al. Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: A propensity score-matched cohort study in primary care. BMC Infect. Dis. 2021;21:262. doi: 10.1186/s12879-021-05951-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-05951-w</ArticleId><ArticleId IdType="pmc">PMC7957446</ArticleId><ArticleId IdType="pubmed">33722197</ArticleId></ArticleIdList></Reference><Reference><Citation>Najmeddin F., Solhjoo M., Ashraf H., Salehi M., Rasooli F., Ghoghaei M., Soleimani A., Bahreini M. Effects of renin-angiotensin-aldosterone inhibitors on early outcomes of hypertensive COVID-19 patients: A randomized triple-blind clinical trial. Am. J. Hypertens. 2021;34:1217&#x2013;1226. doi: 10.1093/ajh/hpab111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajh/hpab111</ArticleId><ArticleId IdType="pmc">PMC8344947</ArticleId><ArticleId IdType="pubmed">34265044</ArticleId></ArticleIdList></Reference><Reference><Citation>Puskarich M.A., Ingraham N.E., Merck L.H., Driver B.E., Wacker D.A., Black L.P., Jones A.E., Fletcher C.V., South A.M., Murray T.A., et al. Angiotensin Receptor Blocker Based Lung Protective Strategies for Inpatients with COVID-19 (ALPS-IP) Investigators. Efficacy of losartan in hospitalized patients with COVID-19-induced lung injury: A randomized clinical trial. JAMA Netw. Open. 2022;5:e222735. doi: 10.1001/jamanetworkopen.2022.2735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.2735</ArticleId><ArticleId IdType="pmc">PMC8928006</ArticleId><ArticleId IdType="pubmed">35294537</ArticleId></ArticleIdList></Reference><Reference><Citation>Fichtenbaum C.J., Gerber J.G. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin. Pharmacokinet. 2002;41:1195&#x2013;1211. doi: 10.2165/00003088-200241140-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-200241140-00004</ArticleId><ArticleId IdType="pubmed">12405866</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna I., Alexander N., Crouthamel M.H., Davis J., Natrillo A., Tran P., Vapurcuyan A., Zhu B. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition. Xenobiotica. 2018;48:300&#x2013;313. doi: 10.1080/00498254.2017.1295171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00498254.2017.1295171</ArticleId><ArticleId IdType="pubmed">28281384</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnanenthiran S.R., Borghi C., Burger D., Caramelli B., Charchar F., Chirinos J.A., Cohen J.B., Cremer A., Di Tanna G.L., Duvignaud A., et al. Renin-angiotensin system inhibitors in patients with COVID-19: A meta-analysis of randomized controlled trials led by the International Society of Hypertension. J. Am. Heart Assoc. 2022;11:e026143. doi: 10.1161/JAHA.122.026143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.122.026143</ArticleId><ArticleId IdType="pmc">PMC9496439</ArticleId><ArticleId IdType="pubmed">36000426</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang N.X., Yuan Q., Fang F., Yan B.P., Sanderson J.E. Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19. PLoS ONE. 2023;18:e0280280. doi: 10.1371/journal.pone.0280280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0280280</ArticleId><ArticleId IdType="pmc">PMC9836310</ArticleId><ArticleId IdType="pubmed">36634085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurdi A., Mueller T., Weir N. An umbrella review and meta-analysis of renin-angiotensin system drugs use and COVID-19 outcomes. Eur. J. Clin. Investig. 2023;53:e13888. doi: 10.1111/eci.13888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13888</ArticleId><ArticleId IdType="pmc">PMC9874890</ArticleId><ArticleId IdType="pubmed">36205627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.M.Y., Docherty K.F., Sattar N., Mehta N., Kalra A., Nowacki A.S., Solomon S.D., Vaduganathan M., Petrie M.C., Jhund P.S., et al. Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from COVID-19: Systematic review and meta-analysis. Eur. Heart J. Cardiovasc. Pharmacother. 2022;8:165&#x2013;178. doi: 10.1093/ehjcvp/pvaa138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvaa138</ArticleId><ArticleId IdType="pmc">PMC7799280</ArticleId><ArticleId IdType="pubmed">33337478</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam S., Ho J.H., Bashir B., Iqbal Z., Ferdousi M., Syed A.A., Soran H. The impact of atherosclerotic cardiovascular disease, dyslipidaemia and lipid lowering therapy on Coronavirus disease 2019 outcomes: An examination of the available evidence. Curr. Opin. Lipidol. 2021;32:231&#x2013;243. doi: 10.1097/MOL.0000000000000763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOL.0000000000000763</ArticleId><ArticleId IdType="pubmed">34116544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lala A., Johnson K.W., Januzzi J.L., Russak A.J., Paranjpe I., Richter F., Zhao S., Somani S., Van Vleck T., Vaid A., et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J. Am. Coll. Cardiol. 2020;76:533&#x2013;546. doi: 10.1016/j.jacc.2020.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.06.007</ArticleId><ArticleId IdType="pmc">PMC7279721</ArticleId><ArticleId IdType="pubmed">32517963</ArticleId></ArticleIdList></Reference><Reference><Citation>Permana H., Huang I., Purwiga A., Kusumawardhani N.Y., Sihite T.A., Martanto E., Wisaksana R., Soetedjo N.N.M. In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): Systematic review and meta-analysis. Pharmacol. Rep. 2021;73:769&#x2013;780. doi: 10.1007/s43440-021-00233-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00233-3</ArticleId><ArticleId IdType="pmc">PMC7895740</ArticleId><ArticleId IdType="pubmed">33608850</ArticleId></ArticleIdList></Reference><Reference><Citation>Lao U.S., Law C.F., Baptista-Hon D.T., Tomlinson B. Systematic review and meta-analysis of statin use and mortality, intensive care unit admission and requirement for mechanical ventilation in COVID-19 patients. J. Clin. Med. 2022;11:5454. doi: 10.3390/jcm11185454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11185454</ArticleId><ArticleId IdType="pmc">PMC9501062</ArticleId><ArticleId IdType="pubmed">36143101</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal R., Banerjee M., Yadav U., Bhattacharjee S. Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis. Postgrad. Med. J. 2022;98:354&#x2013;359. doi: 10.1136/postgradmedj-2020-139172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2020-139172</ArticleId><ArticleId IdType="pubmed">33541927</ArticleId></ArticleIdList></Reference><Reference><Citation>Onorato D., Pucci M., Carpene G., Henry B.M., Sanchis-Gomar F., Lippi G. Protective effects of statins administration in European and North American patients infected with COVID-19: A meta-analysis. Semin. Thromb. Hemost. 2021;47:392&#x2013;399. doi: 10.1055/s-0040-1722307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1722307</ArticleId><ArticleId IdType="pubmed">33482680</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheen A.J. Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies. Diabetes Metab. 2021;47:101220. doi: 10.1016/j.diabet.2020.101220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2020.101220</ArticleId><ArticleId IdType="pmc">PMC7757378</ArticleId><ArticleId IdType="pubmed">33359486</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollias A., Kyriakoulis K.G., Kyriakoulis I.G., Nitsotolis T., Poulakou G., Stergiou G.S., Syrigos K. Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis. Atherosclerosis. 2021;330:114&#x2013;121. doi: 10.1016/j.atherosclerosis.2021.06.911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2021.06.911</ArticleId><ArticleId IdType="pmc">PMC8233054</ArticleId><ArticleId IdType="pubmed">34243953</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahedian-Azimi A., Mohammadi S.M., Banach M., Beni F.H., Guest P.C., Al-Rasadi K., Jamialahmadi T., Sahebkar A. Improved COVID-19 outcomes following statin therapy: An updated systematic review and meta-analysis. BioMed Res. Int. 2021;2021:1901772. doi: 10.1155/2021/1901772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/1901772</ArticleId><ArticleId IdType="pmc">PMC8463212</ArticleId><ArticleId IdType="pubmed">34568488</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Pe&#xf1;a J.D., Katsiki N., Perez-Martinez P. Could statin therapy be useful in patients with coronavirus disease 2019 (COVID-19)? Front. Cardiovasc. Med. 2021;8:775749. doi: 10.3389/fcvm.2021.775749.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.775749</ArticleId><ArticleId IdType="pmc">PMC8578478</ArticleId><ArticleId IdType="pubmed">34778421</ArticleId></ArticleIdList></Reference><Reference><Citation>Santosa A., Franz&#xe9;n S., N&#xe5;tman J., Wettermark B., Parmryd I., Nyberg F. Protective effects of statins on COVID-19 risk, severity and fatal outcome: A nationwide Swedish cohort study. Sci. Rep. 2022;12:12047. doi: 10.1038/s41598-022-16357-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-16357-2</ArticleId><ArticleId IdType="pmc">PMC9282150</ArticleId><ArticleId IdType="pubmed">35835835</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews L., Goldin L., Shen Y., Korwek K., Kleja K., Poland R.E., Guy J., Sands K.E., Perlin J.B. Discontinuation of atorvastatin use in hospital is associated with increased risk of mortality in COVID-19 patients. J. Hosp. Med. 2022;17:169&#x2013;175. doi: 10.1002/jhm.12789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jhm.12789</ArticleId><ArticleId IdType="pmc">PMC9088329</ArticleId><ArticleId IdType="pubmed">35504528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghati N., Bhatnagar S., Mahendran M., Thakur A., Prasad K., Kumar D., Dwivedi T., Mani K., Tiwari P., Gupta R., et al. Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: A randomised clinical trial (RESIST trial) BMC Infect. Dis. 2022;22:606. doi: 10.1186/s12879-022-07570-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07570-5</ArticleId><ArticleId IdType="pmc">PMC9270743</ArticleId><ArticleId IdType="pubmed">35810307</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafoori M., Saadati H., Taghavi M., Azimian A., Alesheikh P., Mohajerzadeh M.S., Behnamfar M., Pakzad M., Rameshrad M. Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial. J. Med. Virol. 2022;94:3160&#x2013;3168. doi: 10.1002/jmv.27710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27710</ArticleId><ArticleId IdType="pmc">PMC9088596</ArticleId><ArticleId IdType="pubmed">35274326</ArticleId></ArticleIdList></Reference><Reference><Citation>Matli K., Al Kotob A., Jamaleddine W., Al Osta S., Salameh P., Tabbikha R., Chamoun N., Moussawi A., Saad J.M., Atwi G., et al. Managing endothelial dysfunction in COVID-19 with statins, beta blockers, nicorandil, and oral supplements: A pilot, double-blind, placebo-controlled, randomized clinical trial. Clin. Transl. Sci. 2022;15:2323&#x2013;2330. doi: 10.1111/cts.13369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.13369</ArticleId><ArticleId IdType="pmc">PMC9350313</ArticleId><ArticleId IdType="pubmed">35808843</ArticleId></ArticleIdList></Reference><Reference><Citation>Hejazi S., Mircheraghi F., Elyasi S., Davoodian N., Salarbashi D., Mehrad-Majd H. Atorvastatin efficacy in the management of mild to moderate hospitalized COVID-19: A pilot randomized triple-blind placebo- controlled clinical trial. Recent Adv. Antiinfect. Drug Discov. 2022;17:212&#x2013;222. doi: 10.2174/2772434417666220902153823.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/2772434417666220902153823</ArticleId><ArticleId IdType="pubmed">36056874</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiggins B.S., Lamprecht D.G., Jr., Page R.L., 2nd, Saseen J.J. Recommendations for managing drug-drug interactions with statins and HIV medications. Am. J. Cardiovasc. Drugs. 2017;17:375&#x2013;389. doi: 10.1007/s40256-017-0222-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40256-017-0222-7</ArticleId><ArticleId IdType="pubmed">28364370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zein A.F.M.Z., Sulistiyana C.S., Khasanah U., Wibowo A., Lim M.A., Pranata R. Statin and mortality in COVID-19: A systematic review and meta-analysis of pooled adjusted effect estimates from propensity-matched cohorts. Postgrad. Med. J. 2022;98:503&#x2013;508. doi: 10.1136/postgradmedj-2021-140409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2021-140409</ArticleId><ArticleId IdType="pubmed">34193549</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle A.J., Thomas W., Retter A., Besser M., MacDonald S., Breen K.A., Desborough M.J.R., Hunt B.J. Updated hospital associated venous thromboembolism outcomes with 90-days follow-up after hospitalisation for severe COVID-19 in two UK critical care units. Thromb. Res. 2020;196:454&#x2013;456. doi: 10.1016/j.thromres.2020.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.10.007</ArticleId><ArticleId IdType="pmc">PMC7543947</ArticleId><ArticleId IdType="pubmed">33065410</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadkarni G.N., Lala A., Bagiella E., Chang H.L., Moreno P.R., Pujadas E., Arvind V., Bose S., Charney A.W., Chen M.D., et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J. Am. Coll. Cardiol. 2020;76:1815&#x2013;1826. doi: 10.1016/j.jacc.2020.08.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.08.041</ArticleId><ArticleId IdType="pmc">PMC7449655</ArticleId><ArticleId IdType="pubmed">32860872</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez D., Garc&#xed;a-Sanchez A., Rali P., Muriel A., Bikdeli B., Ruiz-Artacho P., Le Mao R., Rodr&#xed;guez C., Hunt B.J., Monreal M. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: A systematic review and meta-analysis. Chest. 2021;159:1182&#x2013;1196. doi: 10.1016/j.chest.2020.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.11.005</ArticleId><ArticleId IdType="pmc">PMC7670889</ArticleId><ArticleId IdType="pubmed">33217420</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J.Y., Tan C.W., Wong W.H., Cheong M.A., Lee L.H., Kalimuddin S., Low J.G.H., Ng H.J. Post-hospitalization venous thromboembolism in COVID-19 patients: Evidence against routine post-hospitalization prophylactic anticoagulation. Int. J. Lab. Hematol. 2022;44:e4&#x2013;e7. doi: 10.1111/ijlh.13633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijlh.13633</ArticleId><ArticleId IdType="pmc">PMC8444943</ArticleId><ArticleId IdType="pubmed">34146452</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow J.H., Khanna A.K., Kethireddy S., Yamane D., Levine A., Jackson A.M., McCurdy M.T., Tabatabai A., Kumar G., Park P., et al. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. Anesth. Analg. 2021;132:930&#x2013;941. doi: 10.1213/ANE.0000000000005292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000005292</ArticleId><ArticleId IdType="pubmed">33093359</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelwahab H.W., Shaltout S.W., Sayed Ahmed H.A., Fouad A.M., Merrell E., Riley J.B., Salama R., Abdelrahman A.G., Darling E., Fadel G., et al. Acetylsalicylic acid compared with enoxaparin for the prevention of thrombosis and mechanical ventilation in COVID-19 patients: A retrospective cohort study. Clin. Drug Investig. 2021;41:723&#x2013;732. doi: 10.1007/s40261-021-01061-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-021-01061-2</ArticleId><ArticleId IdType="pmc">PMC8323080</ArticleId><ArticleId IdType="pubmed">34328635</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne T.F., Veigulis Z.P., Arreola D.M., Mahajan S.M., R&#xf6;&#xf6;sli E., Curtin C.M. Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration. PLoS ONE. 2021;16:e0246825. doi: 10.1371/journal.pone.0246825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246825</ArticleId><ArticleId IdType="pmc">PMC7877611</ArticleId><ArticleId IdType="pubmed">33571280</ArticleId></ArticleIdList></Reference><Reference><Citation>Meizlish M.L., Goshua G., Liu Y., Fine R., Amin K., Chang E., DeFilippo N., Keating C., Liu Y., Mankbadi M., et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. Am. J. Hematol. 2021;96:471&#x2013;479. doi: 10.1002/ajh.26102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26102</ArticleId><ArticleId IdType="pmc">PMC8013588</ArticleId><ArticleId IdType="pubmed">33476420</ArticleId></ArticleIdList></Reference><Reference><Citation>Martha J.W., Pranata R., Lim M.A., Wibowo A., Akbar M.R. Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates. Int. J. Infect. Dis. 2021;108:6&#x2013;12. doi: 10.1016/j.ijid.2021.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.05.016</ArticleId><ArticleId IdType="pmc">PMC8123385</ArticleId><ArticleId IdType="pubmed">34000418</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijaya I., Andhika R., Huang I., Purwiga A., Budiman K.Y. The effects of aspirin on the outcome of COVID-19: A systematic review and meta-analysis. Clin. Epidemiol. Glob. Health. 2021;12:100883. doi: 10.1016/j.cegh.2021.100883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cegh.2021.100883</ArticleId><ArticleId IdType="pmc">PMC8556685</ArticleId><ArticleId IdType="pubmed">34754983</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet. 2022;399:143&#x2013;151. doi: 10.1016/S0140-6736(21)01825-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01825-0</ArticleId><ArticleId IdType="pmc">PMC8598213</ArticleId><ArticleId IdType="pubmed">34800427</ArticleId></ArticleIdList></Reference><Reference><Citation>Long B., Chavez S., Carius B.M., Brady W.J., Liang S.Y., Koyfman A., Gottlieb M. Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. Am. J. Emerg. Med. 2022;56:158&#x2013;170. doi: 10.1016/j.ajem.2022.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2022.03.036</ArticleId><ArticleId IdType="pmc">PMC8956349</ArticleId><ArticleId IdType="pubmed">35397357</ArticleId></ArticleIdList></Reference><Reference><Citation>Liverpool Drug Interactions Group  Interactions with Essential Medicines and Nirmatrelvir/Ritonavir.  [(accessed on 12 March 2023)].  Available online:  https://www.covid19-druginteractions.org/</Citation></Reference><Reference><Citation>Reis S., Popp M., Schie&#xdf;er S., Metzendorf M.I., Kranke P., Meybohm P., Weibel S. Anticoagulation in COVID-19 patients&#x2014;An updated systematic review and meta-analysis. Thromb. Res. 2022;219:40&#x2013;48. doi: 10.1016/j.thromres.2022.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.09.001</ArticleId><ArticleId IdType="pmc">PMC9451936</ArticleId><ArticleId IdType="pubmed">36113402</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J., Liu F., Wang Y., Gao M., Nasr B., Lu C., Zhang Q. The effect of previous oral anticoagulant use on clinical outcomes in COVID-19: A systematic review and meta-analysis. Am. J. Emerg. Med. 2022;54:107&#x2013;110. doi: 10.1016/j.ajem.2022.01.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2022.01.059</ArticleId><ArticleId IdType="pmc">PMC8810267</ArticleId><ArticleId IdType="pubmed">35152118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kow C.S., Hasan S.S. Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: A meta-analysis. J. Thromb. Thrombolysis. 2021;52:124&#x2013;129. doi: 10.1007/s11239-021-02436-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02436-0</ArticleId><ArticleId IdType="pmc">PMC8019524</ArticleId><ArticleId IdType="pubmed">33813716</ArticleId></ArticleIdList></Reference><Reference><Citation>Salah H.M., Mehta J.L. Meta-analysis of the effect of aspirin on mortality in COVID-19. Am. J. Cardiol. 2021;142:158&#x2013;159. doi: 10.1016/j.amjcard.2020.12.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2020.12.073</ArticleId><ArticleId IdType="pmc">PMC7834714</ArticleId><ArticleId IdType="pubmed">33417877</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava R., Kumar A. Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis. Int. J. Clin. Pract. 2021;75:e14515. doi: 10.1111/ijcp.14515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14515</ArticleId><ArticleId IdType="pmc">PMC8420464</ArticleId><ArticleId IdType="pubmed">34118111</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>